1. Australia Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Biotron Limited

Biotron Limited

0.00
USD
+0.00
(+15.38%)
0.00EPS
33.08MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
0.01
- -
0.01
0.01
- -
- -
0.01
0.01
- -
- -
- -
- -
Tangible Book Value per Share
0.02
0.01
- -
0.01
0.01
- -
- -
0.01
0.01
- -
- -
- -
- -
Basic Weighted Avg Shares
273
331
331
356
427
432
469
660
772
828
828
938
1,031
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-4
-3
-3
-3
-3
-2
-2
-4
-3
-3
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
8
4
1
4
3
1
1
5
7
4
1
3
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
8
4
1
4
3
1
1
5
7
4
1
3
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-44.58
-60.43
-105.24
-98.45
-82.54
-135.17
-117.11
-47.97
-57.62
-58.96
-112.24
-163.78
- -

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
42.78%
-1.08%
-107.69%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
7.64%
24.45%
-1.61%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Michelle Miller
Full Time Employees
4
Sector
Health technology
Industry
Biotechnology
Address
66 Hunter Street Sydney NSW Australia 2000
IPO Date
Dec 18, 2000
Website
biotron.com.au
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Biotron Limited (ASX:BIT), a clinical-stage biotechnology company founded in 1999 and headquartered in Sydney, Australia, develops and commercializes small molecule antivirals targeting viroporin proteins essential to viruses including HIV-1, hepatitis C virus (HCV), hepatitis B virus (HBV), SARS-CoV-2, dengue, Zika, influenza and respiratory syncytial virus (RSV); its lead product BIT225 advances in Phase 2 trials for HIV-1 and HCV, demonstrating inhibition of HIV replication in macrophage reservoirs to potentially enable viral eradication when combined with antiretrovirals, alongside preclinical HBV candidate BIT-HBV001 showing robust antiviral activity in mouse models and in vitro assays, a proprietary bacterial screening platform supporting a library of over 350 compounds, and early research into SARS-CoV-2 treatments. The company operates primarily in Australia with a global development focus targeting unmet needs in viral infectious diseases for patients and healthcare providers worldwide. In 2025, Biotron announces the acquisition of Sedarex Limited for AU$1.5 million in shares plus milestones, adding SedRx, a patented next-generation general anesthetic with FDA/EMA pathways offering improved safety over prior formulations like Althesin; the deal, subject to shareholder approval and expected completion by December 2025, includes a AU$2.5 million capital raising via placement and rights issue to fund SedRx regulatory advancement, neurological indications and ongoing antiviral programs, diversifying into anesthesia and neuroscience.